Termination of Ventricular Tachycardia with Antitachycardia Pacing after ineffective shock therapy in an ICD recipient with hypertrophic cardiomyopathy

Indian Pacing and Electrophysiology Journal

Volumn 9, Issue 1, 2009, Pages 64-70

  Margos, Panagiotis N ^a   Schomburg, Rolf ^a   Kynast, Jorg ^a   Khattab, Ahmed A ^a   Richardt, Gert ^a  

^a Segeberger Kliniken GmbH   (Germany)

Author keywords

Antitachycardia pacing; Hypertrophic cardiomyopathy; Implantable defibrillator

Indexed keywords

VERAPAMIL;

ADULT; ARTICLE; CARDIOVERSION; CASE REPORT; DEFIBRILLATION; DEFIBRILLATOR; FEMALE; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 67649996086     PISSN: None     EISSN: 09726292     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Schaumann A, von zur Muhlen F, Herse B, et al. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation. 1998; 97: 66-74.
2. Peinado R, Almendral JM, Rius T, et al. Randomized, prospective comparison of four burst pacing algorithms for spontaneous ventricular tachycardia. Am J Cardiol. 1998; 82: 1422-1425.
3. Gillis AM, Leitch JW, Sheldon RS, et al. A prospective randomized comparison of autodecremental pacing to burst pacing in device therapy for chronic ventricular tachycardia secondary to coronary artery disease. Am J Cardiol. 1993; 72: 1146-1151.
4. Swerdlow CD, Russo AM, Degroot PJ. The dilemma of ICD implant testing. Pacing Clin Electrophysiol. 2007;30:675-700.
5. Maron BJ, Spirito P, Shen WK et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12.
6. Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-73.
7. Kwon DH, Setser RM, Popovic ZB et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24:617-25.
8. Mantica M, Della Bella P, Arena V. Hypertrophic cardiomyopathy with apical aneurysm: a case of catheter and surgical therapy of sustained monomorphic ventricular tachycardia. Heart 1997;77:481-3.
9. Schoels W, Steinhaus D, Johnson WB et al. Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: antitachycardia pacing therapy during charging. Heart Rhythm 2007;4:879-85.
10. Jimenez-Candil J, Arenal A, Garcia-Alberola A, et al. Fast ventricular tachycardias in patients with implantable cardioverter-defibrillators: efficacy and safety of antitachycardia pacing. A prospective and randomized study. J Am Coll Cardiol. 2005;45:460-1.
11. Yasuda M, Nakazato Y, Sasaki A. Ventricular fibrillation refractory to ICD therapy. Intern Med. 2005;44:829-31.
12. Papaioannou GI, Kluger J. Ineffective ICD therapy due to excessive alcohol and exercise. Pacing Clin Electrophysiol. 2002;25:1144-5.
13. Watanabe H, Chinushi M, Sugiura H et al. Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length. J Cardiovasc Electrophysiol. 2005;16:262-6.
14. Connolly SJ, Dorian P, Roberts RS et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-71.
15. Hohnloser SH, Dorian P, Roberts R et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006;114:104-9.